Both the baseline levels of CD45RO+/CD8+ T cells (113) and CD8 effector-memory type 1 (EM1) T-cells at baseline (114) can serve as potential biomarker candidates for predicting the clinical outcome of ipilimumab treatment in melanoma. Here, CD8A is linked to melanoma.